翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03378 翰思艾泰-B

待上市 12-18 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本1.36亿
成交额0.00	换手率0.00%	流通股本1,832万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":0,"timestamp":1766044800000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":18321000,"shares":136218830,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-18 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":8,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1766021400000,1766030400000],[1766034000000,1766044800000]],"volumeRatio":0,"ipoDetail":{"name":"翰思艾泰－Ｂ","exchange":"SEHK","listingDate":"2025-12-23","sharesOutstanding":136218830,"sharesFloat":136218830,"offerAmount":18321000,"priceRange":"28.000 - 32.000","market":"HK","openProspectusDate":"2025-12-15","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1215/2025121500028_c.pdf","purchaseBeginDate":"2025-12-15","purchaseEndDate":"2025-12-18","winningDate":"2025-12-22","currency":"HKD","minPurchaseQuantity":100,"peRate":-33.08,"use":"1、约35%或173.7百万港元将用于公司的核心产品（即HX009）的研发；\n2、约33%或163.8百万港元将用于公司的主要产品（即HX301及HX044）的研发；\n3、约17%或84.4百万港元将用于公司其他重要产品的研发；\n4、约5%或25.0百万港元将用于为商业化及╱或业务发展活动提供资金；\n5、约10%或49.4百万港元将用于营运资金及其他一般企业用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的创新生物科技公司，旨在开发新一代免疫疗法。","subscribed":2595.49,"marketCap":3814000000,"minimumCapital":3232.27,"overAllotment":true,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,916000"},"greyMarketDetail":{"greyDate":"2025-12-22","greyDateTimestamp":1766332800000,"greyOpeningTime":1766391300000,"greyClosingTime":1766399400000,"showGreyQuote":false,"openProspectusDate":"2025-12-15","listingDate":"2025-12-23"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":12.65,"timestamp":1766041200000,"preClose":12.84,"halted":0,"volume":62406900,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/03378/wiki","defaultTab":"wiki","newsList":[{"id":"2592124927","title":"新股消息 | 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2592124927","media":"智通财经网","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592124927?lang=zh_cn&edition=full","pubTime":"2025-12-18 14:34","pubTimestamp":1766039696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司翰思艾泰-B于12月15日至12月18日招股，最新已结束招股。根据市场消息，翰思艾泰已获券商借出1472.9亿港元孖展，以公开发售集资额5863万港元计，超购2511倍。翰思艾泰计划发行1832.1万股H股，其中香港公开发售占10%。每股发售价介于28至32港元，每手100股，一手入场费3232.3港元，募资总额最多5.9亿港元。财务方面，于往绩记录期间，翰思艾泰并无盈利，并录得经营亏损。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股消息 | 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2592925492","title":"【新股IPO】国投证券国际：翰思艾泰-B(03378)临床开发领域具备自主核心技术 予IPO专用评分5.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2592925492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592925492?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027259,"startTime":"0","endTime":"0","summary":"翰思艾泰是一家在结构生物学、转化医学及临床开发领域具备自主核心技术与丰富经验的生物科技企业，目前布局有三款肿瘤领域临床阶段候选药物及七款临床前阶段在研药物。核心产品HX009是全球首创及唯一临床开发的PD-1/CD47双特异性抗体及双功能融合蛋白。考虑公司研发管线、港股医药打新市场火热等核心因素，该机构给予公司IPO专用评分“5.7”。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZmY5NDVmYTUwNTRiZmQzZTdjNTQyNTY4MjUwMzQ=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZmY5NDVmYTUwNTRiZmQzZTdjNTQyNTY4MjUwMzQ=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2592591111","title":"智通港股投资日志|12月18日","url":"https://stock-news.laohu8.com/highlight/detail?id=2592591111","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592591111?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:00","pubTimestamp":1765987203,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年12月18日，港股上市公司投资日志如下：    类别 公司  新股活动翰思艾泰-B(招股中)轻松健康(招股中)诺比侃(招股中)华芢生物-B(定价日)印象大红袍(定价日)明基医院(定价日)南华期货股份(定价日) 业绩公布日海天味业英皇资本海丰国际 股东大会召开日新疆新鑫矿业天津银行德林控股辽港股份华滋国际海洋长城汽车广发证券山西安装中国铁塔亨泰 停复牌中金公司（复牌） 分红派息浩德控股（除净日）雅各臣科研制药（派息日）汇丰控股（派息日）滔搏（派息日）百本医护（派息日） 股本增发铁货（除权日）协同通信（除权日）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1535","BK1173"],"gpt_icon":0},{"id":"1183465059","title":"PD-1耐药后的王炸IO，起飞了","url":"https://stock-news.laohu8.com/highlight/detail?id=1183465059","media":"潮药Bar","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183465059?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:10","pubTimestamp":1765962634,"startTime":"0","endTime":"0","summary":"能够在下一个时代里，掀起惊涛骇浪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/qybe22FM2zrKxJr6n31ECg","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1765962698252","symbols":["03378"],"gpt_icon":0},{"id":"1122065346","title":"新一代颠覆级Biotech，潜力爆炸","url":"https://stock-news.laohu8.com/highlight/detail?id=1122065346","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122065346?lang=zh_cn&edition=full","pubTime":"2025-12-17 13:24","pubTimestamp":1765949096,"startTime":"0","endTime":"0","summary":"诺奖级创新，下一代IO核心管线","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/iYX1HVVBO874JduTwtsR2w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1595830015846","symbols":["03378"],"gpt_icon":1},{"id":"2592795703","title":"【新股IPO】国元国际：瀚思艾泰-B(03378)CD47/PD-1双特异性抗体具备独特性 建议谨慎申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2592795703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592795703?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:55","pubTimestamp":1765940103,"startTime":"0","endTime":"0","summary":"2023 年5月获FDA批准开展 HX009 Ib/II 期治疗 DLBCL 研究。公司的管线有独特的竞争优势，截至2025年12 月 1 日，全球无已获批的 CD47/PD-1 双特异性抗体产品，HX009在该靶点组合中处于唯一性地位。上市后市值在 38.14-43.59 亿港元，但考虑到公司的 CD47/PD-1 双特异性抗体有一定的独特性，如果上市之后，产品有较大的潜力，建议谨慎申购。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","03378","BK4023","LU1169590202.USD","BK1535","PD","LU1169589451.USD"],"gpt_icon":1},{"id":"2592912699","title":"翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2592912699","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592912699?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:53","pubTimestamp":1765932783,"startTime":"0","endTime":"0","summary":"翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞调控，布局多款创新机制药物。HX044已获国内联用PD-1抑制剂临床批件。翰思艾泰作为少数拥有两款MCE临床阶段管线的公司之一，具备较强对外授权可能性。BioNTech、和铂医药、中生制药等企业亦在推进靶向TME中Tregs的新型CTLA-4疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"2591515628","title":"智通港股投资日志|12月16日","url":"https://stock-news.laohu8.com/highlight/detail?id=2591515628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591515628?lang=zh_cn&edition=full","pubTime":"2025-12-16 00:00","pubTimestamp":1765814402,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年12月16日，港股上市公司投资日志如下：    类别 公司  新股活动翰思艾泰-B(招股中)轻松健康(招股中)诺比侃(招股中)华芢生物-B(招股中)印象大红袍(招股中)明基医院(招股中)南华期货股份(招股中)智汇矿业(招股中)希迪智驾(招股中)果下科技(上市日) 股东大会召开日武汉有机中国铝业邮储银行宏强控股锦艺集团控股云南水务亚洲果业万科海外精英汇集团汇通达网络 分红派息万成集团股份（除净日）结好控股（除净日）波司登（除净日）弥明生活百货（除净日）网易-S（派息日）达力集团（除净日）亚太资源（派息日）澳洲成峰高教（派息日）","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1173","BK1535"],"gpt_icon":0},{"id":"1183827692","title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183827692","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183827692?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:08","pubTimestamp":1765768110,"startTime":"0","endTime":"0","summary":"12月15日，$翰思艾泰-B $ 发布公告，于12月15日-12月18日招股，公司拟全球发售约1832.1万股股份，预期将于12月23日上市。申购阶梯：每手100股，入场费3232.27港元。乙组门槛为30万股，申购所需资金约969.68万港元。于往绩记录期间及直至最后实际可行日期，公司已在澳大利亚及中国完成HX009的I期临床试验。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":1},{"id":"2591672876","title":"翰思艾泰-B12月15日至12月18日招股 预计12月23日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672876","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591672876?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:03","pubTimestamp":1765753380,"startTime":"0","endTime":"0","summary":"翰思艾泰-B(03378)于2025年12月15日至12月18日招股，该公司拟全球发售1832.1万股，其中香港发售占10%，国际发售占90%，每股发售价28-32港元。每手100股，预期股份将于2025年12月23日在联交 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251215/c673194912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["03378"],"gpt_icon":0},{"id":"2590457696","title":"创新药企扎堆港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457696","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590457696?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:45","pubTimestamp":1765525500,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　12月以来，港股生物医药板块IPO市场热度持续攀升：嘉和生物、翰思艾泰、明基医院、华生物相继通过聆讯，和美药业、高光制药、石药创新、君赛生物陆续递交上市申请，中国证监会国际合作司亦于近期披露英硅智能境外发行上市的备案通知书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161","03378"],"gpt_icon":0},{"id":"2588833998","title":"翰思艾泰通过港交所聆讯，即将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588833998","media":"医药笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588833998?lang=zh_cn&edition=full","pubTime":"2025-12-04 18:39","pubTimestamp":1764844748,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年12月3日，翰思艾泰港交所IPO申请通过聆讯，即将上市。翰思艾泰成立于2014年，2016年起开始搭建研发管线，核心管线HX009为一款PD-1/SIRPα双抗，目前处于二期临床阶段。翰思艾泰成立以来经历多轮融资，2024年8月完成B+轮融资，投后估值16.15亿元。翰思艾泰最新股权结构如下，贝达药业持股5.45%，龙磐资本持股12.43%，金斯瑞持股1.53%。总结翰思艾泰还曾于2016年引进康方生物研发的PD-1抗体HX008，后于2019年转让给乐普生物，并于2022年获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204203627a4ccaba3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204203627a4ccaba3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0052750758.USD","LU0488056044.USD","80388","03378","LU0067412154.USD","LU1282649810.SGD","LU0577902538.SGD","LU0261947096.USD","00388","LU0501845795.SGD","LU0856984785.SGD","LU2039709279.SGD","LU0605514214.HKD","LU0096374516.USD","HEXmain","LU0831103253.SGD","LU0348816934.USD","LU0211977185.USD","LU0791591158.USD","SG9999001846.SGD","IE00BKZH1Z71.USD","LU0630378692.HKD","SG9999001093.SGD","LU0359201612.USD","LU1282648689.USD","BK1610","LU0607220059.USD","LU0873338254.USD","LU0762540952.USD","IE00BZ08YR35.GBP","LU0630378429.USD","LU0197773160.USD","LU0061477393.USD","LU0048580855.USD","LU0561508036.HKD","SGXZ90724238.SGD","LU0516422952.EUR","BK1521","LU0197773673.USD","LU1048596156.SGD","LU0516423174.USD","LU0359201885.HKD","SG9999004220.SGD","LU0577902298.EUR","LU0762541174.USD","LU0149721374.USD","LU0791590937.USD","HKXCY","LU0384037296.USD","LU0797268264.HKD","LU0831093199.SGD"],"gpt_icon":0},{"id":"2588646020","title":"新股消息 | 翰思艾泰通过港交所聆讯 于往绩记录期间产生经营亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2588646020","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588646020?lang=zh_cn&edition=full","pubTime":"2025-12-04 07:01","pubTimestamp":1764802899,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","03378"],"gpt_icon":0},{"id":"2588045735","title":"新股消息 | 翰思艾泰递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045735","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588045735?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:20","pubTimestamp":1764764428,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月3日披露，翰思艾泰生物医药科技(武汉)股份有限公司(简称：翰思艾泰)递表港交所主板，工银国际为其独家保荐人。招股书披露，翰思艾泰是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的生物科技公司。自2016年起，公司开发了产品管线，包括一款核心产品及九款其他管线的候选产品。据悉，核心产品HX009是一种自主研发的抗PD-1(一种免疫检查点受体)/SIRPα双功能抗体融合蛋白。于往绩记录期间及直至最后实际可行日期，公司已在澳大利亚及中国完成HX009的I期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","03378"],"gpt_icon":0},{"id":"2588000317","title":"新股消息 | 翰思艾泰港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2588000317","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588000317?lang=zh_cn&edition=full","pubTime":"2025-12-02 10:02","pubTimestamp":1764640937,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378"],"gpt_icon":0},{"id":"2330654981","title":"厦门港务(000905)3月31日股东户数4.21万户，较上期减少2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2330654981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2330654981?lang=zh_cn&edition=full","pubTime":"2023-04-28 17:43","pubTimestamp":1682675011,"startTime":"0","endTime":"0","summary":"近日厦门港务披露，截至2023年3月31日公司股东户数为4.21万户，较2月28日减少1236.0户，减幅为2.85%。在航运港口行业个股中，厦门港务股东户数低于行业平均水平，截至3月31日，航运港口行业平均股东户数为6.52万户。从股价来看，2023年2月28日至2023年3月31日，厦门港务区间跌幅为3.09%，在此期间股东户数减少1236.0户，减幅为2.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023042800033099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03378","BK0188","000905","BK1173","BK0106","BK0270","BK0000","BK1535"],"gpt_icon":0},{"id":"2330586061","title":"图解厦门港务一季报：第一季度单季净利润同比增16.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2330586061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2330586061?lang=zh_cn&edition=full","pubTime":"2023-04-27 19:27","pubTimestamp":1682594856,"startTime":"0","endTime":"0","summary":"厦门港务2023一季报显示，公司主营收入60.36亿元，同比下降2.25%；归母净利润7682.73万元，同比上升16.61%；扣非净利润5498.18万元，同比上升8.42%；负债率49.45%，投资收益797.93万元，财务费用1019.7万元，毛利率2.85%。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023042700034097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03378","000905"],"gpt_icon":0},{"id":"2330524304","title":"厦门港务(000905.SZ)发一季度业绩，净利润7682.73万元，同比增长16.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2330524304","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2330524304?lang=zh_cn&edition=full","pubTime":"2023-04-27 17:41","pubTimestamp":1682588493,"startTime":"0","endTime":"0","summary":"智通财经APP讯，厦门港务(000905.SZ)发布2023年第一季度报告，营业收入60.36亿元，同比减少2.25%。归属于上市公司股东的净利润7682.73万元，同比增长16.61%。归属于上市公司股东的扣除非经常性损益的净利润5498.18万元，同比增长8.42%。基本每股收益0.1036元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/921246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000905","03378"],"gpt_icon":0},{"id":"2328208427","title":"4月17日厦门港务涨停分析：福建自贸/海西概念，港口，自贸区概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2328208427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2328208427?lang=zh_cn&edition=full","pubTime":"2023-04-17 15:35","pubTimestamp":1681716915,"startTime":"0","endTime":"0","summary":"厦门港务涨停收盘，收盘价7.85元。该股于13点12分涨停，2次打开涨停，截止收盘封单资金为2980.61万元，占其流通市值0.51%。4月17日的资金流向数据方面，主力资金净流入1.47亿元，占总成交额26.91%，游资资金净流出5423.86万元，占总成交额9.92%，散户资金净流出9281.76万元，占总成交额16.98%。近5日资金流向一览见下表：该股为福建自贸/海西概念，港口，自贸区概念热股，当日福建自贸/海西概念概念上涨2.12%，港口概念上涨1.72%，自贸区概念上涨0.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023041700007265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000905","BK1173","BK0270","BK0106","BK0000","BK1535","03378"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hanxbio.com/","compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":-0.0347},{"period":"3month","weight":-0.0405},{"period":"6month","weight":0.0824},{"period":"1year","weight":0.2928},{"period":"ytd","weight":0.2696}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技(武汉)股份有限公司成立于2014年,是一家专注于结构生物学、转化医学及临床开发的创新型生物科技公司。公司致力于开发新一代免疫疗法,为全球患者提供可负担、安全且高效的医疗解决方案,以应对重大疾病挑战。秉持创新驱动的使命与愿景,翰思艾泰专注于发现、研发和商业化用于癌症及自身免疫疾病精准治疗的产品,努力满足全球未被满足的医疗需求,推动疾病的预防、控制和减少,为全球健康事业贡献力量。\n公司科研与管理团队拥有多年在国家重点科研机构及跨国药企从事欧美新药研发、产业化实施和管理的丰富经验。在武汉、杭州、上海、香港、圣地亚哥及澳大利亚,公司已组建了从药物发现到临床研究的完整管理团队,并搭建了拥有全球专利的高亲和力、长半衰期抗体筛选平台,以及肿瘤靶向Geographical Positioning Smallmolecule-Antibody(GPSmAb)创新技术平台。\n目前,翰思艾泰已建立了聚焦肿瘤及免疫疾病的自主创新药物产品管线,并积极开展国际合作项目,为实现全球健康贡献力量。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}